Idaho Medicaid GLP-1 Coverage 2026: Pattern #48 — Operational (Not Statutory) AOM Exclusion Under FFS-Dominant IDHW Architecture, IDAPA 16.03.09.662 Does NOT Enumerate Anti-Obesity Drugs as an Excluded Class, Active Legislative Repeal Trajectory + State-Employee Plan Drop November 1, 2025

TL;DR — what Idaho Medicaid covers and does not cover

The Idaho Medicaid GLP-1 coverage posture per The Rx Index Medicaid GLP-1 50-state tracker verbatim Idaho row:

“Obesity GLP-1 Status: Not covered. Key Notes: Diabetes GLP-1s covered.”

The KFF January 2026 50-state Medicaid coverage of and spending on GLP-1s analysis frames the broader cohort verbatim:

“Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026.”

Idaho is NOT in the KFF January 2026 13-state cohort.

What Idaho Medicaid does NOT cover (obesity / chronic-weight-management indication):

• Wegovy (semaglutide) for obesity
• Zepbound (tirzepatide) for obesity
• Saxenda (liraglutide) for obesity
• Branded fixed-combination Contrave (naltrexone/bupropion) — UNVERIFIED for obesity indication
• Branded fixed-combination Qsymia (phentermine/topiramate) — UNVERIFIED for obesity indication

What Idaho Medicaid DOES cover (presumptively, under federal rebate framework):

• Diabetes-indicated GLP-1 receptor agonists (Ozempic, Rybelsus, Victoza, Trulicity, Mounjaro for T2D) — covered as required under federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8 for rebate-participating manufacturers
• Wegovy SELECT/MACE indication — presumptively covered (federal rebate framework requires coverage of FDA-approved indications other than weight loss); practical PA pathway and criteria UNVERIFIED
• Zepbound moderate-to-severe OSA indication — presumptively covered under federal rebate framework; practical PA pathway and criteria UNVERIFIED
• Wegovy MASH F2/F3 fibrosis indication — presumptively covered under federal rebate framework (FDA approved August 2025); practical PA pathway and criteria UNVERIFIED
• Wegovy pediatric (ages 12+) indication — UNVERIFIED for coverage; Idaho maintains a separate Weight Management benefit for children and adolescents ages 5-21 with overweight / obese BMI (up to $200/year for weight management programs, gym memberships, nutrition classes) — NOT pharmacotherapy

Architectural distinctive features:

• Operational (not statutory) AOM exclusion — IDAPA 16.03.09.662 does NOT enumerate anti-obesity drugs as an excluded class. The exclusion operates through PDL non-preferred status and PA criteria administered by Prime Therapeutics. Administrative carve-back-in does NOT require legislative or formal rulemaking action.
• Ballot-initiative expansion (Proposition 2, November 2018 ~60.6%) — joins UT / ME / NE / MO / OK / SD ballot-initiative-expansion club. Most politically contested expansion architecture in the series.
• Active legislative repeal trajectory — HB 138 (2025) defeated; HB 345 (2025) signed March 19, 2025 (MCO transition by January 1, 2030); HB 913 (2026) signed April 11, 2026 (work requirements by 2027 with three-month lookback). Three consecutive sessions of repeal / restrict bills.
• Predominantly FFS, transitioning to MCO by 2030 — Pattern #48 represents FFS-dominant Medicaid at end-of-life. Healthy Connections PCCM terminated December 31, 2025.
• Sparse rural geography — 44 counties / 83,569 square miles; 10 counties carry only voluntary IMPlus enrollment due to provider scarcity.
• 24-hour PA adjudication standard — IDAPA 16.03.09.663 verbatim: “The Department will respond within twenty-four (24) hours to a request for prior authorization” (faster than federal 72-hour floor).
• State-employee plan compound — Idaho Office of Group Insurance dropped GLP-1 obesity coverage effective November 1, 2025 after estimated spending escalated to $30-$50 million. Politically prefigures any Medicaid GLP-1 expansion question.
• Dual-eligible MCO bifurcation — IMPlus + MMCP for duals only, served by Molina + UnitedHealthcare. Traditional non-dual Medicaid runs through FFS PBM (Prime Therapeutics).
• Independent OAH appeals body — Idaho Office of Administrative Hearings is verbatim “neutral and independent”; ALJs do not work for IDHW. Structurally more independent than the in-agency hearing-officer model used in North Dakota Pattern #44.

Pharmacy benefit architecture:

• PBM: Prime Therapeutics
• Provider PA line (Prime Therapeutics, 24/7/365): 800-922-3987
• Member services: 888-773-9466
• IDHW provider line (Mon-Fri 8am-5pm MT): 208-364-1829 OR 866-827-9967
• PA fax: 800-327-5541
• Electronic PA: CoverMyMeds at covermymeds.health/prior-authorization-forms/idaho-medicaid
• PA form library: publicdocuments.dhw.idaho.gov/WebLink/Browse.aspx?id=3002 (Laserfiche cookie-gated)
• Delivery architecture: FFS-dominant for traditional Medicaid; IMPlus + MMCP for duals only (Molina + UnitedHealthcare); MCO transition delayed to January 1, 2030

1. Federal authority and the operational-vs-statutory distinction

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2) grants states an optional authority to exclude specific drug classes from coverage. Subsection (d)(2)(A) names verbatim “Agents when used for anorexia, weight loss, or weight gain” as one of the optional-exclusion categories. States that wish to exclude AOMs typically codify the exclusion in one of three ways:

1. Statutory exclusion in a freestanding administrative rule that names anti-obesity / anorectic drugs as an excluded class (e.g., Illinois 89 IAC § 140.441(b) categorically excludes “anorectic drugs”; Maine 10-144 C.M.R. ch. 101 Ch. II § 80.06(A) names weight-loss drugs).
2. PDL-codified categorical exclusion in a formal Pharmacy Coverage Policy Manual or Preferred Drug List that lists “weight-loss medications” as a Not Covered bucket (e.g., Montana DPHHS Prescription Drug Program Manual).
3. Operational exclusion by absence or by PA-pathway design — the state has no codified categorical AOM exclusion sentence, but the PA criteria and PDL placement effectively gate access (e.g., South Dakota Pattern #45 where the OptumRx GLP-1 PA form pre-codes only T2D as the indication checkbox).

Idaho falls into the third category — operational exclusion. The binding administrative rule governing Idaho Medicaid pharmacy coverage is IDAPA 16.03.09.662 (“Prescription Drugs: Coverage and Limitations”). The rule enumerates drug classes that Idaho Medicaid excludes from coverage under the federal optional-exclusion authority:

• Fertility agents
• Cosmetic / hair-growth agents
• Cough-and-cold agents
• Erectile-dysfunction agents

Anti-obesity / weight-loss drugs are NOT in the IDAPA 16.03.09.662 enumerated exclusion list. This is structurally significant: Idaho has chosen NOT to codify the AOM exclusion in administrative rule, even though the federal optional-exclusion authority is available. The exclusion operates instead through:

• PDL non-preferred status for Wegovy, Zepbound, Saxenda (PDL hosted on Laserfiche, cookie-gated, not directly retrievable)
• PA criteria that limit obesity-indicated GLP-1s to T2D-only indications (per the “Diabetes GLP-1s covered” framing in The Rx Index)
• Absence of a publicly posted obesity-indication PA pathway

The bar to administrative carve-back-in is LOWER in Idaho than in statutory-exclusion states. IDHW or the Pharmacy and Therapeutics Committee could reverse the policy through the standard quarterly PDL revision process by adding Wegovy / Zepbound / Saxenda as preferred or non-preferred agents with publicly posted PA criteria for the obesity indication. No legislative action is required. No formal IDAPA rulemaking under the Idaho Administrative Procedure Act is required. The change would be implemented through the same administrative process that adds, removes, or repositions any other drug on the PDL.

Conversely, the lower administrative bar means IDHW could also tighten the policy without legislative action — the absence of a codified categorical exclusion does not provide statutory protection against further restrictions.

2. IDAPA 16.03.09.662 / 663 anchor: the binding administrative rules

2.1 IDAPA 16.03.09.662 — Prescription Drugs: Coverage and Limitations

IDAPA 16.03.09.662 is the binding Idaho Administrative Procedures Act rule governing prescription drug coverage and limitations under Idaho Medicaid. The rule enumerates the drug classes that Idaho Medicaid excludes under the federal optional-exclusion authority at 42 U.S.C. § 1396r-8(d)(2). As detailed in Section 1, the enumerated exclusion list includes fertility agents, cosmetic / hair-growth agents, cough-and-cold agents, and erectile-dysfunction agents — but NOT anti-obesity / weight-loss drugs.

Source: law.cornell.edu IDAPA 16.03.09.662.

2.2 IDAPA 16.03.09.663 — Prior Authorization

IDAPA 16.03.09.663 governs Idaho Medicaid prior authorization. Three operative provisions:

PA decision criteria verbatim:

“FDA labeling, recognized drug information compendia, peer-reviewed medical literature including systematic reviews and randomized controlled trials, and comparative clinical outcomes.”

Adjudication timeline verbatim:

“The Department will respond within twenty-four (24) hours to a request for prior authorization.”

Emergency supply verbatim:

“at least a 72-hour supply in emergencies without prior approval.”

The 24-hour adjudication standard is materially FASTER than the federal 72-hour floor for routine PA decisions under 42 CFR § 440.230 and faster than the standard adjudication window in most peer states in the 50-state series.

Source: law.cornell.edu IDAPA 16.03.09.663.

2.3 What is NOT codified in IDAPA 16.03.09

Notably absent from IDAPA 16.03.09:

• No categorical “weight-loss drugs not covered” sentence
• No “anti-obesity drugs not covered” sentence
• No “anorectic drugs not covered” sentence
• No FDA-label-restricted carve-out language for Wegovy SELECT/MACE, Zepbound OSA, or Wegovy MASH (these indications are presumptively covered under the federal rebate framework but the specific PA criteria are not codified in IDAPA)
• No SPA-based carve-back-in language (e.g., Mississippi Pattern #35 SPA 23-0013)

The Idaho Medicaid Preferred Drug List (PDL) is the operative coverage policy document, but it is hosted on the IDHW Laserfiche WebLink portal (publicdocuments.dhw.idaho.gov/WebLink/DocView.aspx?id=15075) which is cookie / session-gated and not retrievable via direct URL fetch. PA forms are similarly hosted on the Laserfiche portal at publicdocuments.dhw.idaho.gov/WebLink/Browse.aspx?id=3002.

3. Delivery system: FFS-dominant with IMPlus / MMCP duals-only MCO overlay

3.1 Traditional Medicaid — fee-for-service

The Idaho Medicaid traditional (non-dual-eligible) population — including children, parents, pregnant women, disabled adults, seniors, and the ACA Medicaid expansion population — is administered through fee-for-service. Healthy Connections, Idaho’s legacy primary care case management (PCCM) program that operated as a low-touch care-coordination layer over FFS, terminated December 31, 2025. The Idaho Medicaid traditional Medicaid program operates as pure FFS with no PCCM overlay through at least the start of MCO procurement under HB 345.

3.2 MCO transition delayed to January 1, 2030

HB 345 (2025), signed by Governor Brad Little March 19, 2025, directs IDHW to transition Idaho Medicaid from FFS to a comprehensive managed-care model with MCO procurement to follow. The transition is delayed to January 1, 2030. The four-year-plus transition timeline gives IDHW time to procure MCOs, negotiate contracts, transition pharmacy benefit administration (currently Prime Therapeutics), and establish MCO oversight infrastructure. The transition timeline overlaps with the federal §1115 waiver submission required under HB 913 (work requirements by 2027), creating a compound administrative burden on IDHW.

For GLP-1 coverage specifically, the FFS-dominant period through 2030 means PDL revisions and PA criteria changes operate through the existing IDHW / P&T Committee process. After the MCO transition, GLP-1 coverage may diverge between FFS legacy beneficiaries and MCO-enrolled beneficiaries depending on MCO formulary discretion.

3.3 Idaho Medicaid Plus (IMPlus) — dual-eligible managed care

Idaho Medicaid Plus (IMPlus) serves dual-eligibles — individuals enrolled in both Medicaid and Medicare. IMPlus enrollment is:

• Mandatory in 34 of 44 counties
• Voluntary in 10 sparsely populated counties: Bear Lake, Butte, Camas, Caribou, Custer, Franklin, Lemhi, Lewis, Oneida, Teton

The voluntary IMPlus counties share two characteristics: low population density and limited MCO provider networks. Voluntary IMPlus enrollment allows dual-eligibles in these counties to remain in FFS Medicaid if MCO provider access would be impaired.

3.4 Medicare Medicaid Coordinated Plan (MMCP)

MMCP serves dual-eligibles who select coordinated Medicare + Medicaid through a single integrated plan. MMCP integrates the dual-eligible’s Medicare Advantage plan and Medicaid plan into a single coordinated benefit, reducing fragmentation of care and pharmacy benefit administration.

3.5 MCOs operating in IMPlus / MMCP

Two MCOs operate in IMPlus / MMCP:

• Molina Healthcare of Idaho
• UnitedHealthcare Community Plan of Idaho

Each MCO administers its own pharmacy benefit for IMPlus / MMCP enrollees, which may include MCO-specific PDL placement for GLP-1 receptor agonists. UNVERIFIED whether the Molina or UnitedHealthcare IMPlus / MMCP PDL deviates from the FFS Prime Therapeutics-administered PDL on AOM coverage specifically.

3.6 Carve-out service administrators

• Behavioral health: Magellan Healthcare
• Dental: MCNA (operating under the brand “Idaho Smiles”)

4. Enrollment and Proposition 2 ballot-initiative expansion

4.1 Enrollment numbers

Per healthinsurance.org February 2026 (citing Medicaid.gov):

“312,807 – Number of Idahoans covered by Medicaid/CHIP as of October 2025”

“88,751 – Number of Idahoans covered by ACA Medicaid expansion as of June 2025”

Expansion population represents approximately 28% of total Medicaid / CHIP enrollment — meaningfully larger than expansion’s share in older expansion states because Idaho expansion is newer (effective January 1, 2020) and the working-age non-disabled adult population is the fastest-growing category in state Medicaid.

4.2 Proposition 2 — November 2018 ballot initiative

Idaho voters approved Proposition 2 on November 6, 2018 with approximately 60.6% yes. Proposition 2 expanded Medicaid eligibility to adults aged 19-64 with incomes up to 138% of the Federal Poverty Level under the ACA Medicaid expansion authority at 42 U.S.C. § 1396a(a)(10)(A)(i)(VIII). Expansion took effect January 1, 2020.

Idaho joins approximately 7 states that expanded Medicaid by direct voter ballot initiative:

• Maine (2017)
• Idaho, Nebraska, Utah (2018)
• Missouri, Oklahoma (2020)
• South Dakota (2022)

Ballot-initiative expansion states share a structural feature: expansion was adopted over opposition from the Republican-controlled state legislature, which has resulted in repeated legislative attempts to add restrictions, sunset triggers, or work requirements to the program. Idaho’s legislative repeal trajectory (Section 6 below) reflects this pattern.

5. PA pathway and submission process

5.1 T2D-indicated GLP-1 PA criteria

T2D-indicated GLP-1 receptor agonists (Ozempic, Rybelsus, Victoza, Trulicity, Mounjaro) are covered under Idaho Medicaid per the federal rebate framework. The specific PA criteria for each agent — including A1c thresholds, step-therapy requirements, and tier placement (preferred vs. non-preferred) — are codified on the Idaho Medicaid PDL hosted on the IDHW Laserfiche portal at publicdocuments.dhw.idaho.gov/WebLink/DocView.aspx?id=15075. The portal is cookie / session-gated and the specific PDL content is UNVERIFIED via direct URL fetch.

Typical state Medicaid T2D GLP-1 PA criteria include: documented T2D diagnosis with ICD-10 E11.x family; A1c documentation; step-therapy with metformin and/or SGLT-2 inhibitor before non-preferred GLP-1 agents; endocrinology or primary care prescribing.

5.2 Anti-obesity pathway: no covered pathway

There is no Idaho Medicaid PA pathway for the obesity / chronic-weight-management indication of Wegovy, Zepbound, or Saxenda. Claims submitted with obesity diagnosis codes (E66.x family) will be denied as non-covered regardless of BMI, comorbidities, or clinical justification.

5.3 Federal-rebate-framework carve-outs (Wegovy MACE, Zepbound OSA, Wegovy MASH)

Federal Medicaid drug rebate rules at 42 U.S.C. § 1396r-8 require coverage of FDA-approved indications other than weight loss for rebate-participating manufacturers. The Wegovy SELECT/MACE indication (FDA approved March 2024), the Zepbound moderate-to-severe OSA indication (FDA approved December 2024), and the Wegovy MASH indication (FDA approved August 2025) are presumptively covered under Idaho Medicaid under the federal rebate framework. However, the practical PA criteria, step-therapy requirements, and adjudication outcomes are UNVERIFIED in publicly available IDHW / Prime Therapeutics documentation.

For prescribers seeking access to these carve-outs, the practical pathway:

1. Document the FDA-approved indication other than weight loss (cardiology consult note for SELECT/MACE; in-lab sleep study for OSA; F2/F3 fibrosis documentation for MASH).
2. Submit a PA via CoverMyMeds at covermymeds.health/prior-authorization-forms/idaho-medicaid or fax to 800-327-5541, citing the FDA label and clinical justification.
3. If the PA is denied as “weight loss not covered,” appeal citing the federal rebate framework requirement that Idaho cover FDA-indicated drugs other than for weight loss.
4. If the appeal is denied at the IDHW level, file a Request for Hearing within 28 days of the denial notice.

5.4 Submission contacts

• Prime Therapeutics Pharmacy Support Center (24/7/365): 800-922-3987
• IDHW provider line (Mon-Fri 8am-5pm Mountain Time): 208-364-1829 OR 866-827-9967
• PA fax: 800-327-5541
• Member services: 888-773-9466
• Electronic PA: CoverMyMeds Idaho Medicaid ePA
• PA form library: publicdocuments.dhw.idaho.gov/WebLink/Browse.aspx?id=3002 (Laserfiche cookie-gated)

5.5 24-hour PA adjudication standard

Per IDAPA 16.03.09.663 verbatim: “The Department will respond within twenty-four (24) hours to a request for prior authorization.” This 24-hour standard is materially FASTER than the federal 72-hour floor under 42 CFR § 440.230 for routine PA decisions and faster than the standard adjudication window in most peer states in the 50-state series.

5.6 72-hour emergency supply

Per IDAPA 16.03.09.663 verbatim: “at least a 72-hour supply in emergencies without prior approval.” The 72-hour emergency supply provides a bridge for time-sensitive scenarios where the PA cannot be adjudicated within the prescribing window — the pharmacy can dispense a 72-hour supply without prior approval, and the PA can be submitted retrospectively.

6. Appeals pathway: 28-day window, OAH neutral / independent

6.1 Filing deadline: 28 days from postmark

Idaho Medicaid uses a 28-day filing window for pharmacy decisions and other medical-services decisions. The 28-day window applies verbatim to:

“denial of medical services and supports, transportation, independent assessment, hospital or residential behavioral health care, pharmacy, and any other medical decisions.”

Pharmacy decisions including GLP-1 PA denials fall into this category. The 28-day window runs from the postmark date of the denial notice mailed to the beneficiary.

Note on the 28-day vs. 30-day distinction: IDHW separately lists a 30-day window for general “Medicaid” eligibility / enrollment decisions, but the 28-day window is the operative deadline for pharmacy / medical-services denials. Counsel should confirm the operative window with the specific denial-notice language in case of ambiguity.

6.2 Expedited 72-hour decision for urgent scenarios

Expedited review with a 72-hour decision is mandated if the standard 90-day adjudication timeline would jeopardize the beneficiary’s health verbatim:

“waiting up to ninety (90) days for a final decision will jeopardize your: life, physical or mental health, or your ability to attain, maintain, or regain maximum [function].”

The expedited pathway is appropriate for beneficiaries with active cardiovascular events, sleep-apnea-related cardiopulmonary instability, advanced MASH with fibrosis progression, or other clinically urgent scenarios where GLP-1 access is time-sensitive.

6.3 Filing methods

• Mail: Self-Reliance Programs, P.O. Box 83720, Boise, ID 83720-0026
• Email: mybenefits@dhw.idaho.gov
• Fax (toll-free): 866-434-8278
• Phone (toll-free): 877-456-1233

6.4 Office of Administrative Hearings (OAH) — neutral and independent

The Idaho Office of Administrative Hearings (OAH) is the hearing body that adjudicates Idaho Medicaid appeals after the initial IDHW review. OAH is verbatim “neutral and independent” — the administrative law judges (ALJs) who hear Idaho Medicaid appeals do NOT work for IDHW. This structurally separates the adjudicative function from the agency that issued the denial.

• Address: Office of Administrative Hearings, P.O. Box 83720, Boise, ID 83720-0104
• Phone: (208) 605-4300
• Email: general@oah.idaho.gov
• Governing rule: IDAPA 16.05.03 (DHW Contested Case Rules)

The OAH neutral-and-independent model is the same architecture used in Kansas Pattern #43 (Kansas OAH in Topeka) and is structurally more independent than the in-agency hearing-officer model used in North Dakota Pattern #44 (where the NDDHHS hearing officer is an NDDHHS employee operating in an adjudicative capacity).

6.5 Practical denial-recovery strategy

1. First, call Prime Therapeutics Pharmacy Support Center at 800-922-3987. Many Idaho Medicaid GLP-1 PA denials are documentation deficiencies recoverable via re-submission of the same PA with additional clinical evidence. Common deficiency patterns: missing T2D ICD-10 code; missing step-therapy documentation (metformin trial, SGLT-2 inhibitor trial); missing prescriber specialty designation; missing A1c documentation.
2. If the denial is substantive, re-submit the PA with stronger evidence. For obesity-indication denials, the federal-rebate-framework appeal (asserting Idaho cannot exclude FDA-indicated drugs other than for weight loss) is the operative legal anchor. Document the specific FDA-approved indication (SELECT/MACE, OSA, MASH) and cite the indication-specific clinical evidence.
3. If re-submission fails, file the Request for Hearing within 28 days of the denial notice postmark. Submit via mail to Self-Reliance Programs, P.O. Box 83720, Boise, ID 83720-0026; or email mybenefits@dhw.idaho.gov; or fax 866-434-8278; or phone 877-456-1233. Request aid-paid-pending (coverage continues during the appeal).
4. For urgent scenarios, request expedited review citing the 72-hour decision mandate when standard adjudication would jeopardize life, physical or mental health, or ability to attain maximum function.
5. If the IDHW review affirms the denial, the case proceeds to OAH. The OAH ALJ is neutral and independent. Beneficiaries may represent themselves, retain counsel, or seek representation from Idaho Legal Aid Services.
6. If the OAH ALJ affirms the denial, the further appeal is to Idaho District Court under the Idaho Administrative Procedure Act. The District Court reviews the administrative record under the appropriate standard of review.

7. Active legislative repeal trajectory: HB 138, HB 345, HB 913

Idaho has seen three consecutive sessions of Medicaid-restricting legislation. The cumulative effect is increasing administrative friction on expansion enrollment, even though Proposition 2 expansion remains in place as of May 15, 2026.

7.1 HB 138 (2025 session) — DEFEATED

HB 138 was sponsored by Rep. Jordan Redman (R-Coeur d’Alene). The bill included 11 “sideboards” on Medicaid expansion:

• Work requirements for expansion enrollees
• Enrollment cap at 50,000
• Ban on Medicaid expansion eligibility after 3 years on the program
• Marketplace-subsidy option for 100-138% FPL beneficiaries
• Automatic repeal trigger of Medicaid expansion if all 11 sideboards are not implemented OR if the federal funding match drops below 90%

Status: cleared the Idaho House; held in Senate committee; did NOT pass.

Source: Idaho Legislative Assembly — HB 138 (2025).

7.2 HB 345 (2025 session) — SIGNED March 19, 2025

HB 345 was sponsored by the House Health and Welfare Committee. Vote tallies:

• House: 61-9-0 (March 6, 2025)
• Senate: 29-6-0 (March 11, 2025, rules suspended)
• Signed by Gov. Brad Little: March 19, 2025

Provisions:

• Requires legislative approval for state plan amendments (SPAs) and § 1115 waivers
• Directs IDHW to transition Idaho Medicaid from fee-for-service to a comprehensive managed-care model
• MCO procurement to follow
• Transition delayed to January 1, 2030

Source: Idaho Legislative Assembly — HB 345 (2025).

7.3 HB 913 (2026 session) — SIGNED April 11, 2026

HB 913 was signed by Governor Brad Little on April 11, 2026, effective immediately. Provisions:

• Implements Medicaid expansion work requirements by 2027
• Requires § 1115 waiver submission
• Three-month lookback period for employment-status verification

Sen. Julie VanOrden (R-Pingree) characterized the three-month lookback verbatim:

“long enough to ensure people don’t just get a job weeks before they apply to Medicaid.”

Sen. Melissa Wintrow (D-Boise) characterized the bill verbatim:

“backdoor [attempt to repeal expansion]”

Source: Idaho Capital Sun — HB 913 passage (March 31, 2026); KMVT — Gov. Little signs HB 913 (April 11, 2026).

7.4 Pharmacy-specific legislation

No state legislation in the past 24 months has specifically addressed GLP-1 or AOM Medicaid coverage in Idaho. The legislative trajectory is focused on Medicaid expansion eligibility restrictions, MCO transition, and work requirements — not on PDL-level AOM coverage decisions. The absence of pharmacy-specific legislation is consistent with the operational (not statutory) nature of the AOM exclusion in Idaho: the policy is administered through PDL revisions and PA criteria, which do not require legislative action.

8. State-employee plan compound: OGI dropped GLP-1 obesity coverage November 1, 2025

The Idaho Office of Group Insurance (OGI) — which administers the state-employee health plan, NOT Medicaid — discontinued GLP-1 coverage for weight loss effective November 1, 2025. Per public reporting and the OGI September 2025 Health Highlights newsletter, spending on GLP-1s for weight loss escalated to verbatim “$30 to $50 million (estimated)” under the OGI plan, which precipitated the coverage discontinuation.

This is NOT a Medicaid policy — OGI covers state employees, not Medicaid beneficiaries — but the OGI drop politically prefigures any Medicaid GLP-1 coverage question in Idaho. Three compounding effects:

1. Fiscal framing: if the state-employee plan dropped GLP-1 obesity coverage on fiscal grounds at $30-$50M annualized spending, the legislative and budgetary appetite for adding it to Medicaid (a substantially larger population with substantially higher spending exposure) is correspondingly reduced.
2. Symbolic precedent: the state-employee plan is often viewed as a public policy bellwether. Its decision to drop a benefit creates a symbolic precedent that other Idaho payers (including Medicaid) can follow without political cost.
3. Stakeholder alignment: state employees are an organized political constituency. Their acceptance of the GLP-1 coverage drop without public opposition reduces the political cost of similar Medicaid restrictions.

For Idaho Medicaid specifically, the OGI drop creates political compounding that makes an administrative carve-back-in of AOM coverage less likely — even though the IDAPA framework allows for it without legislative action.

Source: Idaho Freedom Foundation — state-employee GLP-1 spending; OGI September 2025 Health Highlights newsletter.

9. UNVERIFIED items — flagged honestly

Per Weight Loss Rankings’ YMYL 125% accuracy standard, the following items are flagged as UNVERIFIED rather than fabricated. These are gaps in the publicly accessible Idaho Medicaid primary sources that readers should verify independently:

1. Direct PDL retrieval. The Idaho Medicaid Preferred Drug List is hosted on the IDHW Laserfiche WebLink portal (publicdocuments.dhw.idaho.gov) which is cookie / session-gated and not retrievable via direct URL fetch. Specific line-level PA criteria for T2D-indicated GLP-1 agents (Ozempic, Rybelsus, Victoza, Trulicity, Mounjaro) are UNVERIFIED.
2. Wegovy SELECT/MACE practical PA pathway. The Wegovy CV indication is presumptively covered under the federal rebate framework, but the specific Idaho Medicaid PA criteria (age window, BMI thresholds, CVD documentation requirements, step-therapy) are UNVERIFIED.
3. Zepbound OSA practical PA pathway. The Zepbound OSA indication is presumptively covered under the federal rebate framework, but the specific Idaho Medicaid PA criteria (AHI threshold, sleep-study type, CPAP-trial requirements, weight-management-program prerequisites) are UNVERIFIED.
4. Wegovy MASH practical PA pathway. The Wegovy MASH indication (FDA approved August 2025) is presumptively covered under the federal rebate framework, but the specific Idaho Medicaid PA criteria (F2/F3 fibrosis documentation modality, specialist requirements, alcohol-abstinence biomarkers) are UNVERIFIED.
5. IMPlus / MMCP pharmacy carve-out structure. UNVERIFIED whether the Molina Healthcare of Idaho or UnitedHealthcare Community Plan of Idaho IMPlus / MMCP PDL deviates from the FFS Prime Therapeutics-administered PDL on AOM coverage specifically. Default assumption is parity, but each MCO has independent formulary discretion.
6. Pediatric Wegovy coverage pathway (ages 12+). UNVERIFIED. Idaho maintains a separate Weight Management benefit for children and adolescents ages 5-21 with overweight / obese BMI (up to $200/year for weight management programs, gym memberships, nutrition classes) — this is NON-pharmacotherapy. The pediatric Wegovy obesity-indication coverage pathway is UNVERIFIED. EPSDT (42 U.S.C. § 1396d(r)) provides a federal floor for medical necessity in beneficiaries under 21.
7. HB 913 § 1115 waiver text + CMS denial / approval scenarios. HB 913 requires submission of a § 1115 waiver to CMS to implement the work requirements by 2027. UNVERIFIED whether the waiver has been submitted, the specific waiver text, or CMS’s response to the submission.
8. Contrave / Qsymia branded combination coverage status. UNVERIFIED whether Contrave (naltrexone/bupropion) and Qsymia (phentermine/topiramate) are covered as branded fixed-combination products. The components (naltrexone, bupropion, phentermine, topiramate) are typically available for non-obesity indications on most state Medicaid PDLs.
9. Idaho commercial EHB Benchmark GLP-1 / GIP coverage status. UNVERIFIED whether the Idaho commercial ACA-marketplace EHB Benchmark Plan includes GLP-1 / GIP weight-loss coverage like North Dakota’s 2025 EHB Benchmark does.
10. Expedited fair-hearing operational details. The 72-hour expedited decision standard is codified, but operational details (how to invoke expedited review, what evidence supports the “jeopardize life, physical or mental health” standard) are UNVERIFIED in publicly available IDHW documentation.

If you encounter any of these gaps in practice, please contact us with the documentation and we will update this article with verified primary-source language.

10. How Idaho Pattern #48 fits the 50-state series

Idaho Pattern #48 is an operational-exclusion-by-non-codification state — the IDAPA framework does NOT enumerate anti-obesity drugs as an excluded class, but the PDL placement and PA criteria operate to exclude AOMs in practice. The 50-state series to date documents seven coverage-architecture types:

10.1 ID vs. South Dakota (Pattern #45) — closest operational-exclusion peer

Both Idaho and South Dakota are operational-exclusion states with no codified categorical AOM exclusion sentence. Key differences:

• Codification mechanism: SD operates the exclusion through the OptumRx-administered SD-specific GLP-1 PA form, which pre-codes only T2D as the indication checkbox; the exclusion is form-based. ID operates the exclusion through IDAPA 16.03.09.662’s silence on AOMs combined with PDL placement and PA criteria; the exclusion is rule-silence-based.
• Delivery architecture: SD is FFS-only (no comprehensive risk-based MCOs; KFF May 2025 Managed Care < 0.5%). ID is FFS-dominant with IMPlus + MMCP duals-only MCO overlay (Molina + UnitedHealthcare); the comprehensive MCO transition is delayed to 1/1/2030.
• PBM: SD uses OptumRx. ID uses Prime Therapeutics.
• Ballot-initiative expansion: ID Proposition 2 approved November 2018 ~60.6%, effective 1/1/2020. SD Constitutional Amendment D approved November 8, 2022 with 56.21% yes, effective 7/1/2023. ID expansion is older and more entrenched; SD expansion is newer and faces an active constitutional sunset trigger (Amendment I on the November 3, 2026 ballot would condition expansion on FMAP ≥ 90%).
• Legislative repeal trajectory: ID has active repeal trajectory (HB 138 defeated 2025; HB 345 signed MCO-by-2030; HB 913 signed work-requirements-by-2027). SD has the unique constitutional sunset trigger on the Nov 3, 2026 ballot.
• PA adjudication standard: ID 24 hours (IDAPA 16.03.09.663 verbatim). SD 72 hours (Pharmacy Services manual verbatim “Most PA requests are adjudicated within 72 hours”).
• Appeals hearing body: ID Office of Administrative Hearings (neutral / independent). SD Office of Administrative Hearings (at 700 Governors Drive, Pierre, SD 57501).

10.2 ID vs. Montana (Pattern #46) — pure codified categorical peer

MT has a clean codified categorical chronic-weight-management exclusion (“weight-loss medications” Not Covered bucket in DPHHS Prescription Drug Program Manual); ID has NO codified categorical exclusion. MT uses PCCM (Passport to Health) for traditional Medicaid; ID’s Healthy Connections PCCM terminated 12/31/2025 leaving ID FFS-only for traditional Medicaid. The structural distinction: MT’s codified categorical exclusion means administrative carve-back-in requires PDL revision PLUS removal of the categorical sentence from the DPHHS manual. ID’s non-codified exclusion means administrative carve-back-in requires only PDL revision and publication of obesity-indication PA criteria.

10.3 ID vs. North Dakota (Pattern #44) — codified middle-ground peer

ND is the codified middle-ground “covered for everything except obesity” state with explicit codified carve-outs in PDL 2026.4 (Wegovy MACE, Wegovy MASH, Zepbound OSA, antipsychotic-induced weight gain without PA, Imcivree, low-cost AOM components without PA). ID’s carve-outs are presumptively available under the federal rebate framework but the specific PA criteria are UNVERIFIED in publicly accessible documentation. ND’s codified pathway gives prescribers a clear roadmap for the SELECT/MACE, MASH, and OSA indications; ID’s non-codified pathway requires prescribers to assert federal-rebate-framework coverage and navigate a denial-recovery process.

10.4 ID vs. Kansas (Pattern #43) — legislative-trajectory contrast

KS covers Wegovy + Zepbound for standalone obesity at adult BMI ≥ 30 or ≥ 27 with comorbidity; KS LOOSENED criteria in 2024-2025 by de-listing both drugs from Table 4. ID does NOT cover AOMs for obesity; ID’s legislative trajectory is in the opposite direction (HB 138 / HB 345 / HB 913 all restrict expansion or transition delivery). KS uses OAH at Topeka for fair hearings; ID uses OAH at Boise. Both KS OAH and ID OAH are neutral / independent (ALJs do not work for the agency that issued the denial).

10.5 ID vs. Rhode Island (Pattern #40) — inverse coverage trajectory

RI currently covers baseline AOM (Wegovy, Zepbound, Saxenda, Contrave for obesity) but faces a governor-proposed October 1, 2026 sunset; ID excludes baseline AOM. Where RI patients ask “will my existing coverage survive the legislature?”, ID patients ask “is the IDHW administrative carve-back-in pathway politically viable given the state-employee plan drop and the legislative repeal trajectory?”

10.6 ID vs. Vermont (Pattern #41) — codification-vs-non-codification contrast

VT anchors a codified categorical bundled exclusion (“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth”) AND codifies three FDA-label-restricted carve-outs in the FFS PDL. ID has neither the codified categorical exclusion sentence nor the codified carve-outs — the exclusion operates through non-codification (silence in IDAPA + PDL placement + PA criteria). VT’s codified architecture gives both patients and prescribers a clear primary-source reference; ID’s non-codified architecture forces prescribers to rely on federal-rebate-framework assertions and PA-denial-recovery processes.

11. What Idaho Medicaid beneficiaries should do right now

If you have type 2 diabetes: diabetes-indicated GLP-1 receptor agonists (Ozempic, Rybelsus, Victoza, Trulicity, Mounjaro) are covered under Idaho Medicaid per the federal rebate framework. Your prescriber should submit the PA via Prime Therapeutics at 800-922-3987 or via CoverMyMeds. Specific tier placement (preferred vs. non-preferred), step-therapy requirements, and A1c thresholds are determined by the Idaho Medicaid PDL (hosted on the IDHW Laserfiche portal). Adjudication is within 24 hours per IDAPA 16.03.09.663.

If you have established cardiovascular disease and meet SELECT/MACE criteria (prior MI, or prior stroke + PAD): the Wegovy SELECT/MACE indication (FDA approved March 2024) is presumptively covered under the federal Medicaid drug rebate framework that requires coverage of FDA-approved indications other than weight loss. Your prescriber should submit the PA citing the FDA label, the cardiology consult note, and the indication-specific clinical evidence. If the PA is denied as “weight loss not covered,” appeal citing the federal rebate framework. Specific Idaho Medicaid PA criteria are UNVERIFIED but typical state Medicaid SELECT/MACE criteria include BMI 27.0-34.9, age 55-74 (matching SELECT trial population), no T2D, and concurrent statin + antiplatelet therapy.

If you have moderate-to-severe obstructive sleep apnea (AHI > 15 on sleep study) AND BMI ≥ 30: the Zepbound OSA indication (FDA approved December 2024) is presumptively covered under the federal rebate framework. Your prescriber should submit the PA with the in-lab attended polysomnography report, sleep-medicine specialist consult, and BMI documentation. Practical PA criteria UNVERIFIED.

If you have biopsy-proven or non-invasive-test-confirmed F2/F3 MASH: the Wegovy MASH indication (FDA approved August 2025) is presumptively covered under the federal rebate framework. Your prescriber should engage an endocrinologist, gastroenterologist, or hepatologist; document F2/F3 fibrosis via biopsy, vibration-controlled transient elastography, ELF score, MR-PDFF, or MR elastography; and submit the PA with the indication-specific clinical evidence. Practical PA criteria UNVERIFIED.

If you have obesity without one of the above qualifying indications: Idaho Medicaid does NOT cover Wegovy, Zepbound, or Saxenda for the obesity / chronic-weight-management indication. The Rx Index tracker is verbatim explicit: “Not covered.” There is no obesity-indication PA pathway. The IDAPA framework allows for administrative carve-back-in (no codified categorical exclusion exists), but as of May 15, 2026 no public IDHW or P&T Committee proposal to add AOM coverage exists.

If you are a child or adolescent (ages 5-21) with overweight or obese BMI: Idaho maintains a separate Weight Management benefit providing up to $200/year for weight management programs, gym memberships, and nutrition classes — this is NON-pharmacotherapy. Pediatric Wegovy obesity-indication coverage is UNVERIFIED. EPSDT (42 U.S.C. § 1396d(r)) provides a federal floor for medical necessity in beneficiaries under 21.

If you cannot access Idaho Medicaid GLP-1 coverage: practical paths are (1) NovoCare Wegovy cash-pay ($199-$349/month standard pens; $399/month high-dose pen; $149/month oral semaglutide tablets per May 15, 2026 NovoCare verification — the $499 baseline was retired in May 2026); (2) LillyDirect Zepbound vials at $299-$699/month; (3) LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026) at $149/month self-pay; (4) patient assistance programs (Novo Nordisk PAP, Lilly Cares) income-tested; (5) LegitScript-approved compounded telehealth at $99-$199/month for semaglutide and $149-$249/month for tirzepatide (FDA compounding-resolved caveat applies for both molecules); (6) if you transition above 138% FPL to commercial ACA-marketplace coverage, your specific commercial plan’s formulary may cover GLP-1s for obesity (Idaho commercial EHB coverage status UNVERIFIED).

If your PA is denied: do not give up after the first denial. Call Prime Therapeutics at 800-922-3987 to verify denial rationale — many Idaho Medicaid GLP-1 PA denials are documentation deficiencies recoverable via re-submission with stronger evidence. For FDA-indicated drugs other than for weight loss (Wegovy MACE, Zepbound OSA, Wegovy MASH), the federal-rebate-framework appeal is the operative legal anchor. If re-submission fails, file the Request for Hearing within 28 days of the denial notice postmark. Submit via mail to Self-Reliance Programs, P.O. Box 83720, Boise, ID 83720-0026; email mybenefits@dhw.idaho.gov; fax 866-434-8278; or phone 877-456-1233. For urgent scenarios, request expedited 72-hour review. If the IDHW review affirms the denial, the case proceeds to OAH (Office of Administrative Hearings, P.O. Box 83720, Boise, ID 83720-0104; (208) 605-4300; general@oah.idaho.gov; rule IDAPA 16.05.03).

Related coverage

• North Dakota Medicaid GLP-1 Coverage (Pattern #44) — middle-ground “covered for everything except obesity” state with CODIFIED carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA + antipsychotic-induced + Imcivree + low-cost AOM components) in PDL 2026.4; PBM Acentra Health; HB 1451 / HB 1452 FAILED 12-81 / 11-82 on House floor February 12, 2025 — the most decisive legislative no-vote in series. Codified contrast to Idaho’s non-codified operational exclusion.
• South Dakota Medicaid GLP-1 Coverage (Pattern #45) — closest operational-exclusion peer to Idaho: SD also has NO codified categorical AOM exclusion sentence (operational exclusion by absence); SD operates exclusion through OptumRx GLP-1 PA form pre-coding T2D only as indication checkbox; FFS-only architecture; ballot-initiative expansion (Amendment D 2022 56.21% yes); Constitutional Amendment I (90% FMAP trigger) on November 3, 2026 ballot.
• Montana Medicaid GLP-1 Coverage (Pattern #46) — clean CODIFIED categorical “weight-loss medications” Not Covered bucket in DPHHS Prescription Drug Program Manual; PCCM (Passport to Health) architecture; HB 245 made expansion permanent; SB 417 (Sen. Ellie Boldman AOM mandate) died 11-1 in committee March 1, 2025. Codified-categorical contrast to Idaho’s non-codified operational exclusion.
• Kansas Medicaid GLP-1 Coverage (Pattern #43) — positive-coverage non-expansion state that LOOSENED AOM criteria 2024-2025 by de-listing Wegovy + Zepbound from Table 4 (BMI ≥ 40 severe-obesity gate eliminated); inverse trajectory to Idaho’s legislative repeal trajectory. Both states use OAH (neutral / independent) as the hearing body.
• Vermont Medicaid GLP-1 Coverage (Pattern #41) — codified categorical bundled exclusion (“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth”) PLUS codified Wegovy MACE + Wegovy MASH + Zepbound OSA carve-outs in FFS PDL; FFS-only architecture. Codification-vs-non-codification contrast to Idaho’s non-codified posture.
• Rhode Island Medicaid GLP-1 Coverage (Pattern #40) — first state in series with active coverage + governor-proposed October 1, 2026 sunset; inverse coverage trajectory to Idaho. RI patients ask “will coverage survive the legislature?”; ID patients ask “is the IDHW administrative carve-back-in pathway politically viable?”
• West Virginia Medicaid GLP-1 Coverage (Pattern #36) — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs via WVU RDTP
• Mississippi Medicaid GLP-1 Coverage (Pattern #35) — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages 12+ pathway
• Oklahoma Medicaid GLP-1 Coverage (Pattern #24) — categorical exclusion + 3 FDA-label carve-outs (Wegovy CV + Wegovy MASH + Zepbound OSA)
• 50-state Medicaid GLP-1 coverage map — full series overview with pattern taxonomy
• GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
• GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states

Primary sources

1. IDAPA 16.03.09.662 — Prescription Drugs: Coverage and Limitations (law.cornell.edu)
2. IDAPA 16.03.09.663 — Prior Authorization (law.cornell.edu)
3. IDHW Idaho Medicaid Pharmacy Program (provider landing)
4. IDHW Managed Care (IMPlus / MMCP landing)
5. IDHW Appeals and Fair Hearings
6. IDHW Adult Medicaid including Expansion
7. IDHW Pharmacy and Therapeutics Committee
8. Idaho Office of Administrative Hearings — Information for the Public
9. Idaho Medicaid PDL (Laserfiche WebLink, cookie-gated)
10. Idaho Medicaid PA form directory (Laserfiche WebLink, cookie-gated)
11. CoverMyMeds Idaho Medicaid ePA
12. Idaho Legislative Assembly — HB 138 (2025)
13. Idaho Legislative Assembly — HB 345 (2025)
14. Idaho Capital Sun — HB 138 (February 4, 2025)
15. Idaho Capital Sun — HB 913 passage (March 31, 2026)
16. KMVT — Gov. Little signs HB 913 (April 11, 2026)
17. KFF Medicaid Coverage of and Spending on GLP-1s (January 2026)
18. The Rx Index Medicaid GLP-1 50-state tracker
19. healthinsurance.org Idaho Medicaid
20. Idaho Freedom Foundation — state-employee GLP-1 spending
21. Idaho Office of Group Insurance — September 2025 Health Highlights
22. Medicaid Planning Assistance — Idaho Medicaid Plus (IMPlus)
23. UHC Community Plan Idaho PDL
24. Molina Healthcare of Idaho Medicaid Plus PDL